MedCity and the Japan BioIndustry Association is organising an event to promote collaboration and knowledge exchange between the London life science ecosystem and Japanese Pharma.
Japan BioIndustry Association (JBA) is a non-profit organization. The organization is planning for sound development in bioscience-related industries and is dedicated to solving problems on a global scale through advances in bioscience. JBA is contributing to society in various areas from the development of advanced technology to the development of industry.
JBA’s membership base spans a wide array of businesses in biotechnology. In addition, JBA counts public organizations, universities, public research institutes and a variety of individuals as members. This makes JBA is a uniquely positioned to comprehensively promote the advancement of bioindustries through the cooperation of industry, academia, and government.
MedCity and JBA have a long lasting relationship, promoting each other life science sector, facilitating interaction between Japanese and UK organisations and stimulating new business opportunities.
Discussions will cover Japanese pharma, new trends and approaches in focus areas of advanced therapies, health data and Imaging/AI.
With the upcoming BioJapan annual conference taking place from 13-15 October this is a great opportunity to find out more about the benefits of collaboration with Japan and how partnering at this event could help forge those important partnerships.
Kindly moderated by Dr Ivana Poparic, Head of Clusters Development at MedCity, with introduction from Prof Yoshiaki Tsukamoto, Executive Director at the Japan BioIndustry Association.
The webinar would feature speakers from Japanese Pharmaceutical companies, such as Asahi Kasei Pharma Corporation, Daiichi Sankyo and Takeda Pharmaceuticals.
Speakers from the London ecosystem would represent companies focusing on health data, advanced therapies, and Imaging/AI:
Mr Alex Blyth, Founder, LIfT BioSciences
LIfT Biosciences is a UK & EU based Biotech currently closing a major funding round with a leading pharma fund to bring to clinic a 1st in class allogeneic innate cell therapy called Neutrophil Only Leukocyte Infusion Therapy (N-LIfT). N-LIfT has the game-changing potential to destroy all solid tumours irrespective of mutation or strain. N-LIfT uses a special type of N1a neutrophil with special cancer killing and immune recruitment capabilities. Our vision is to develop the world’s first cell bank of mass produced ‘cancer killing neutrophils’ to deliver a portfolio of immuno-oncology cell therapies for delivering complete remission in all solid tumours.
Mr Dusan Saska, Business Development Lead, Discover Now, Imperial College Health Partners
Discover-NOW, the Health Data Research Hub for Real World Evidence, aims to revolutionise the way health data is used responsibly for research into treating and preventing disease. Led by Imperial College Health Partners, brings together NHS organisations, globally recognised academic, industry, technology, research and charity partners as well as patients and the public focussed on the use of real-world health data for research. Launched in November 2019 Discover-NOW is one of seven Health Data Research Hubs funded through the UK Research and Innovation Industrial Strategy Challenge Fund and delivered through Health Data Research UK– the national institute for health data science.
Prof Sebastien Ourselin, Head of School of Biomedical Engineering & Imaging Sciences, King’s College and Deputy Director of the AI Centre for Value Based Healthcare
The London Medical Imaging & Artificial Intelligence Centre for Value Based Healthcare (AI Centre), was established in February 2019 as part of the UK Government’s Industrial Strategy Challenge Fund and delivered through UK Research and Innovation (UKRI). Led by King’s College London and Guy’s and St Thomas’ NHS Foundation Trust, the AI Centre is made up of 10 NHS Trusts, 4 Universities and Industry partners. Our partnerships combine expertise in AI, medical imaging, and data science from leaders in industry, research, and clinical practice around the world.
The presentations would be followed by a Q&A session to help understand areas of further interest and collaboration.
To sign up, please register here